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so at 10 years there is a standard deviation of about 14%.
Our data are fairly similar and go along with the other largeA
C
DDrKenton J. Zehr (Baltimore, Md). I thank the Association for
the opportunity to discuss the manuscript, and I thank you,
Dr Goldstone, for a copy well in advance of the meeting. I have
no disclosures.
I applaud the University of Pennsylvania group in helping us to
understand the fate of mitral valve repair for various pathologies
over the past many years. Their series is large enough to provide
a clue into the effect on the right side of the heart.
Of your series of more than 4000 patients, your included cohort
was only 10% of the total group, and of these, only 43% had grade
1 to 3 tricuspid regurgitation (TR). This seems like a small number
according to the total group of 4000 patients. Was your exclusion
criteria too aggressive?
Dr Goldstone. That is an excellent question. The 4200 patients
were all-comers for mitral valve surgery, including any other
concomitant procedure, such as a root replacement. One thousand
patients had isolated mitral valve surgery, but that did include
concomitant atrial ablation.
Because of the potential influence of atrial fibrillation on TR
progression, and because recent studies have shown differences
in etiology of mitral disease affecting progression of TR, we
limited our study population to patients with degenerative mitral
valve disease who underwent isolated mitral valve surgery,
excluding patients with concomitant atrial ablations. That is why
we ended up with 500 patients.
This was the particular patient cohort I wanted to look at
because the most recent studies in patients with degenerative
mitral valve disease argued against concomitant tricuspid
annuloplasty, but our guidelines do not distinguish between
disease etiology, and I think that is something that we need more
data on moving forward.
Dr Zehr. The median follow-up time was 3.4 years. So this
really is an intermediate-term follow-up study. Although you
reported 10-year freedom from TR at 63%, there were only 7
patients at risk at that time point. So if you back up and look at
the 5-year follow-up, the freedom from significant TR was 90%,
which I would determine to be an excellent result.
So if you look at the data in a different way at an intermediate
follow-up, the TR increase was relatively inconsequential with
regard to symptoms and by grade. There is really only a 1.5+
overall increase in patients with grade 0 to 2+ preop, and indeed,
among the 37 patients that had +3 preop, they actually got better
over time at intermediate follow-up. No additional valve work is
without risk, and tricuspid annuloplasty carries a small risk of
increased need for pacemaker and an increased risk of
endocarditis.The Journal of Thoracic and CarShould the conclusion be the opposite? That is, in patients with
degenerative disease, the tricuspid valve should be left alone?
Is this TR clinically relevant?
Dr Goldstone. That is a very good point and I think our
conclusions are slightly controversial, but this is a controversial
topic.
In terms of the midterm study, I agree, our median follow-up
was 3.5 years, but that is why we conducted actuarial analyses,
which demonstrate the overall trend. At the longest follow-up,
more than 10 years after surgery, freedom frommoderate or severe
TR would be estimated to be 64%. But the error bars do increase,
studies in patients with degenerative mitral valve disease, such
as that by Yilmaz and colleagues as well as the Cleveland Clinic
study. Although the Mayo Clinic argued that nonsevere functional
TR is unlikely to progress in these patients, they did use the mean
grade of TR. Taking the mean of an ordinal variable can be
misleading, especially because such data may be skewed. The
authors did include a table that showed that at 5 years after surgery,
30% of patients had grade 3 or 4 TR, which is similar to the trend in
our population. I believe the Cleveland Clinic data showed a
similar trend, and actually at 3 years after surgery the patients
with more significant preoperative TRwho did not have a tricuspid
valve repair already recurred to their prior grade of TR. In terms of
the patients with moderate preoperative TR, they also seem to
progress more quickly to recurrent moderate TR.
Dr Zehr. Seventy-three percent were reported to have
follow-up echos. Do we know what happened to the other 27%
of patients? Were they happy and healthy and thus no need for
an echo or were they lost to follow-up?
Dr Goldstone. They were lost to follow-up.
Dr Steven F. Bolling (Ann Arbor, Mich). This is a very nice
series in a controversial area. In light of the Dreyfus paper that
shows that the addition of a tricuspid annuloplasty at the time of
a mitral does not add to the operative mortality and in light of
the Calafiore paper that says that the operative mortality may
actually go down with the addition of a tricuspid annuloplasty in
those patients, we applaud your aggressive approach.
In the real world, do you do a preventative tricuspid
annuloplasty? What is your criteria now to do an annuloplasty
while you are there?
Dr Goldstone. We just came across these data at this meeting.
The reason we do not have a comparison group is because
currently at our institution wewill repair the tricuspid valve if there
is concomitant severe TR. So our comparison group would have
been only about 30 patients and they would have all had severe
preoperative TR.
Dr Woo is going to become more aggressive with performing
concomitant tricuspid annuloplasty in patients with a dilated
tricuspid annulus who are undergoing mitral valve surgery.
Dr Bolling. In light of those data, do you think this calls for a
randomized, large prospective trial in this group of patients?
Dr Goldstone. I have been trying to come up with a good
way to conduct a randomized controlled trial in this group of pa-
tients for quite some time. The main issue that we run into is
selecting a satisfiable clinical end point. First of all, the trial
would need to be fairly long depending on what type of mitral
valve disease etiology is selected in the study. Progression of TRdiovascular Surgery c Volume 148, Number 6 2809
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Dis definitely faster in patients with functional or ischemic mitral
regurgitation, and I think that has to do with concomitant right
ventricular dysfunction in those patients versus a patient with
mitral valve prolapse. But you are still going to have to create
a study that spans many years, as well as choose an appropriate
clinical end point. Unfortunately, in my opinion New York Heart
Association functional class is a poor metric for right heart
function. I did not have data on diuretic use, liver transaminases,
or kidney function. I believe that in a clinical trial a surrogate end
point, such as right ventricular dimensions or function in addition
to grade of tricuspid regurgitation, would need to be used.
However I definitely agree that a randomized prospective trial
would be ideal to help inform the cardiac surgery community on
this controversial issue.
Dr Harold L. Lazar (Boston, Mass). Did you measure
pulmonary artery (PA) pressures either by echo or by cath and
have you found that to be a determinant of what ultimately happensEDITORIAL CO
See related article on pages 2802-10.
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high PA pressures at the time of mitral valve replacement or
repair tend to be the ones who tend to have increased TR in the
future.
Dr Goldstone. We did look at PA pressures. They were
measured by right heart catheterization, and preoperative mean
PA pressure was not a significant predictor of progression of TR
postoperatively in univariate analysis. That is consistent with the
Mayo paper, which did not find pulmonary artery pressure to be
a significant predictor either. I agree that it makes sense that
pulmonary hypertension would influence TR progression.
Perhaps the reason why different studies identify different
predictors of TR progression alludes to the multifactorial nature
of functional TR.
Dr Lazar. In those patients who had progressive TR, did their
PA pressures go up or did they stay the same?
Dr Goldstone. I do not have longitudinal data on PA pressure.MMENTARYThe role of cognitive dissonance in the management of functional
tricuspid regurgitation at the time of degenerative mitral valve repairRakesh M. Suri, MD, DPhil,a and Yan Topilsky, MDbCognitive dissonance: Psychologic conflict resulting
from incongruous beliefs and attitudes held
simultaneously.
In this issue of the Journal, Goldstone and colleagues1
from the University of Pennsylvania and Stanford have
assembled the third largest series (n¼ 495) in the literature
of patients with mitral valve prolapse undergoing mitral
valve repair with coexistent functional tricuspid valve
regurgitation (TR) not surgically managed. Forty-three
percent of patients had anywhere between trivial to
moderately severe TR at mitral valve repair, and freedomfrom greater than moderate TR was approximately 60%
at 9 years. Older age and grade of preoperative TR pre-
dicted progression; and ‘‘some degree’’ of right ventricular
dysfunction was more frequent in those with severe TR
during follow-up.
What does this study tell us? The findings reaffirm those
published from the Mayo Clinic in 2011 and in 2014.2,3 Our
institution’s first series studied 699 patients who underwent
mitral valve repair for isolated degenerative leaflet prolapse
and moderate or less coexistent functional TR. We
identified that moderate TR actually regressed with time
in most cases after successful and durable repair of
degenerative mitral valve disease. Indeed, only 1 patient
out of the entire series required reoperation for
progressive TR 4.5 years after mitral valve repair. Our
most recent report expanded on this analysis, studying
747 adult patients with mitral valve prolapse among
whom 683 underwent mitral valve repair and 64 had
replacement. We found no difference in the occurrence of
moderately severe or severe TR after mitral valve repair
versus replacement and found the univariate predictors of
TR progression to be older age, female sex, higher
pulmonary arterial pressure, and larger left atrial size.
Only 2 patients required reoperation for late functional
TR. The report of Goldstone and colleagues1 thus adds togery c December 2014
